Over the past decade, our knowledge regarding the cellular and molecular mechanisms involved in NASH- and NAFLD-associated HCC development has grown, spotlighting GLP-1 RAs, which had originally emerged as drugs for the management of diabetes, as potential candidates for the treatment of HCC. This evidence concerns the gene GCG and hepatocellular carcinoma.